<DOC>
	<DOC>NCT00440648</DOC>
	<brief_summary>This is a double-blind, randomized, cross-over study conducted at centers within the United States. The study consists of five periods: an up to two-week Screening Period, a 5-week Run-In Period, two eight-week study treatment periods and a two-week Washout Period. Patients are assigned randomly (1:1) to one of two treatment sequences: sevelamer carbonate for eight weeks followed by sevelamer hydrochloride for eight weeks or sevelamer hydrochloride for eight weeks followed by sevelamer carbonate for eight weeks</brief_summary>
	<brief_title>Cross-Over Study of Sevelamer Hydrochloride and Sevelamer Carbonate</brief_title>
	<detailed_description>The study was conducted at 15 centers (2 of which did not enroll any patients). A total of 79 hemodialysis patients were assigned randomly to one of two treatment sequences.</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<criteria>patient had received hemodialysis three times per week for 3 months or longer; patients were maintained on sevelamer hydrochloride as their primary phosphate binder with a total daily dose of ≤ 13.6 g with serum phosphorus concentrations at the last two measurements between 3.0 and 6.5 mg/dL, the most recent iPTH ≤ 600 pg/mL and the most recent serum calcium within the normal range. if patient had active bowel obstruction, dysphagia, swallowing disorders, or severe gastrointestinal motility disorders; active ethanol or drug abuse (excluding tobacco); need for antidysrhythmic or antiseizure medications used to control these conditions; poorly controlled diabetes mellitus or hypertension; active vasculitis; active malignancy other than basalcell carcinoma; HIV infection; or any clinically significant unstable medical condition as judge by the Investigator.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>